Skip to main content

Advertisement

SpringerLink
Log in

Tumor-infiltrating lymphocytes as antitumor effector cells

  • Published:
Biotherapy

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Nathanson L. Spontaneous regression of malignant melanoma. A review of the literature on incidence, clinical features and possible mechanisms.Conference on Spontaneous Regression of Cancer. Nat Cancer Inst Monogr 1976; 44: 67–77.

    Google Scholar 

  2. Bodurtha AL. Spontaneous regression of malignant melanoma. In: Clark WH, Jr., Goldman LI, Mastrangelo MJ, eds. Human Malignant Melanoma. New York: Grune & Stratton, 1979: 227–41.

    Google Scholar 

  3. Starzl TE, Nalesnik MA, Porter KA, Ho M, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporine-steroid therapy. Lancet 1985; 1: 584–7.

    Google Scholar 

  4. Penn I. Tumors arising in organ transplant recipients. Adv Cancer Res 1978; 28: 31–61.

    Google Scholar 

  5. Ho M, Jaffe R, Miller G, Breinig MK, et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative after transplantation and its manifestations in children. Transplantation 1988; 45: 719–27.

    Google Scholar 

  6. Ioachim HL. The stroma reaction of tumors: An expression of immune surveyance. JNCI 1979; 57: 465–75.

    Google Scholar 

  7. Wolfe GT, Hudson JL, Peterson KA, Miller HL, McClatchey KD. Lymphocyte subpopulations infiltrating squamous carcinomas of the head and neck: correlations with extent of tumor and prognosis. Otol Head & Neck Surg 1986; 95: 142–51.

    Google Scholar 

  8. Bystryn J-C, Oratz R, Harris MN, Roses DF, Golomb FM, Speyer JL. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 1988; 61: 1065–70.

    Google Scholar 

  9. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with metastatic cancer. NEJM 1985; 313: 1485–92.

    Google Scholar 

  10. Schirrmacher V. Shifts in tumor cell phenotypes induced by signals from the microenvironment. Revelance for the immunobiology of cancer metastasis. Immunobiol 1980; 157: 89–98.

    Google Scholar 

  11. Allouche M, Sahkaoui Y, Augery-Bourget Y, Ohashi Y, Sugamura K, Jasmin C, Georgoulias V. Presence of a p70 IL-2-binding peptide on leukemia cells from various hematopoietic lineages. J Immunol 1989; 142: 2223–9.

    Google Scholar 

  12. Sacchi M, Heo DS, Dahl C, Johnson JT, Herberman RB, Whiteside TL. Interleukin 2 receptors on human squamous cell carcinoma lines. Proc. ACCR, 31: 305, 1990.

    Google Scholar 

  13. Snyderman R, Cianciolo GJ. Immunosuppressive activity of retroviral envelope protein p15E and its possible relationship to neoplasia. Immunol Today 1984; 5: 2404.

    Google Scholar 

  14. Shu S, Chou T, Rosenberg SA. Generation from tumor-bearing mice of lymphocytes within vivo therapeutic efficacy. J Immunol 1987; 139: 295–8.

    Google Scholar 

  15. Whiteside TL, Heo DS, Tagaki S, Johnson JT, Iwatsuki S, Herberman RB. Cytolytic anti-tumor cells in longterm cultures of human tumor infiltrating lymphocytes in recombinant interleukin 2. Cancer Immunol Immunother 1988; 26: 1–10.

    Google Scholar 

  16. Heo DS, Whiteside TL, Kanbour A, Herberman RB. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu19 (NKH1-positive recombinant IL2-activated cultures of lymphocytes infiltrating human ovarian tumors. J Immunol 1988; 140: 4042–9.

    Google Scholar 

  17. Takagi S, Chen K, Schwarz R, Iwatsuki S, Herberman RB, Whiteside TL. Functional and phenotypic analysis of tumor infiltrating lymphocytes isolated from human primary and metastatic liver tumors and cultured in recombinant IL2. Cancer 1989; 63: 102–11.

    Google Scholar 

  18. Whiteside TL, Herberman RB. Serum and tissue banks for biological markers. In: Herberman RB, Mercer RW, eds: Immunodiagnosis of cancer. New York: Marcel Dekker, Inc., 1990: 55–68.

    Google Scholar 

  19. Whiteside TL, Miescher S, Hurlimann J, Moretta L, Von Fliedner V. Separation, phenotyping and limiting dilution analysis of lymphocytes infiltrating human solid tumors. Int J Cancer 1986; 37: 806–11.

    Google Scholar 

  20. Whiteside TL, Miescher S, MacDonald RH, Von Fliedner V. Separation of tumor-infiltrating lymphocytes from human solid tumors. A comparison of velocity sedimentation and discontinuous density gradients. J Immunol Methods 1986; 90: 221–33.

    Google Scholar 

  21. Whiteside TL. Human tumor-infiltrating lymphocytes and their characterization. In: Lotzova E, Herberman RB, eds. Interleukin-2 and killer cells in cancer. Boca Raton, FL: CRC Press, 1990: 130–51.

    Google Scholar 

  22. Vose BM, Moore M. Human tumor-infiltrating lymphocytes: A marker of host response. Semin Hematol 1985; 22: 27–40.

    Google Scholar 

  23. Whiteside TL, Miescher S, Hurlimann J, Moretta L, Von Fliedner V. Clonal analysis andin situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother 1986; 23: 169–78.

    Google Scholar 

  24. Hata K, Zhang XR, Iwatsuki S, Van Thiel DH, Herberman RB, Whiteside TL. Isolation, phenotypic and functional analysis of lymphocytes from human liver. Clin. Immunol Immunopath 1990; 56: 401–19.

    Google Scholar 

  25. Poppema S, Bracket EB, DeLeij L, Terback D, Visscher T, Terhaar A, MAcher E, The TH, Sorg C. In situ analysis of the mononuclear cell infiltrate in primary malignant melanoma of the skin. Clin Exp Immunol 1983; 51: 77–82.

    Google Scholar 

  26. Van Duinen SG Ruiter DJ, Broecker EB, et al. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res 1988; 48: 1019–25.

    Google Scholar 

  27. Lopez-Nevot MA, Garcia E, Pareja E, Bonal FJ, Martin J, Ruiz-Cabelo F, Serrano S, Garkido F. Differential expression of HLA antigens in primary and metastatic melanomas. J Immunogenetics 1986; 13: 219–27.

    Google Scholar 

  28. Miescher S, Stoeck M, Whiteside TL, et al. Altered activation pathways in T lymphocytes infiltrating human solid tumors. Transplantation Proc 1988; 20: 344–6.

    Google Scholar 

  29. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, Von Fliedner V. Proliferative and cytolytic potentials of purified human tumor-infiltrating T lymphocytes. Impaired response to mitogen-driven stimulation despite T-cell receptor expression. Int J Cancer 1988; 42: 659–66.

    Google Scholar 

  30. Whiteside TL, Heo DS, Takagi S, Herberman RB. Tumor-infiltrating lymphocytes from human solid tumors: Antigen-specific killer T lymphocytes or activated natural killer lymphocytes. In: Stevenson HC, ed: Adoptive Cellular Immunotherapy of Cancer. New York: Marcel Dekker, Inc., 1989: 139–57.

    Google Scholar 

  31. Massaro A, Ward MM, Evans SS, Stewart C, Foon K, Ward RE. Preferential expression of theγ/δ TCR in T cells infiltrating B cell lymphomas. Proc AACR 1989; 30: 344.

    Google Scholar 

  32. Shimizu Y, Iwatsuki S, Herberman RB, Whiteside TL. Clonal analysis of tumor-infiltrating lymphocytes from human primary and metastatic liver tumors. Int J Cancer 1990; 46: 878–83.

    Google Scholar 

  33. Snyderman CH, Heo DS, Chen K, Whiteside TL, Johnson JT. T cell in tumor-infiltrating lymphocytes of head and neck cancer. Head & Neck 1989; 11: 331–6.

    Google Scholar 

  34. Vaccarello L, Wang Y.L., Whiteside TL. Sustained outgrowth of autotumor-reactive T lymphocytes from human solid tumors in the presence of tumor necrosis factor a and interleukin 2. Human Immunol 1990; 28: 216–27.

    Google Scholar 

  35. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells and involvement of the T cell receptor. J Exp Med 1988; 168: 1419–41.

    Google Scholar 

  36. Cardi G, Mastrangelo MJ, Berd D. Deletion of T-cells with the CD4+CD45R+ phenotype in lymphocytes that infiltrate subcutaneous metastases of human melanoma. Cancer Res 1989; 49: 6562–5.

    Google Scholar 

  37. Finke JH, Tubbs R, Connely B, Pontes E, Montie J: Tumor infiltrating lymphocytes in patients with renal cell carcinoma. Ann NY Acad Sci 1988; 532: 387–94.

    Google Scholar 

  38. Bilik R, Mor C, Hazaz B, Moroz C. Characterization of T lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol Immunother 1989; 28: 143–7.

    Google Scholar 

  39. Rabinowich H, Cohen R, Bruderman L, Steiner Z, Klajman A. Functional analysis of mononuclear cells infiltrating into tumors: Lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res 1987; 47: 173–7.

    Google Scholar 

  40. Moore K, Walters MT, Jones DB, Garvey E, Harvey J, Cawley MID, Smith JL. An immunohistological study of CD4+ lymphocyte subsets within inflammatory lesions with special reference to rheumatoid arthritis and inflammatory bowel disease. Immunology 1988; 65: 457–63.

    Google Scholar 

  41. Pitzalis C, Kinglsey G, Haskard D, Panayi G. The preferential accumulation of helper-inducer T lymphocytes in inflammatory lesions: evidence for regulation by selective endothelial and homotypic adhesion. Eur J Immunol 1988, 18: 1397–404.

    Google Scholar 

  42. Cozzolino F, Torcia M, Castigh E, Selli C, Giordani R, Carossino AM, Squadrelli M, Cagnoni M, Pistoia V, Ferrarini M. Presence of activated T-cell with a T8+M1+-Leu7+ surface phenotype in invaded lymph nodes from patients with solid tumors. JNCI 1986; 77: 637–41.

    Google Scholar 

  43. Cozzolino F, Torcia M, Carossino AM, Giordani R, Selli C, Talini G, Reali E, Novelli A, Pistoia V, Ferrarini M. Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response. J Exp Med 1987; 166: 303–18.

    Google Scholar 

  44. Snyderman CH, Heo DS, Johnson JT, D'Amico F, Whiteside TL. Functional and phenotypic analysis of lymphocytes isolated from the tumor and lymph nodes in head and neck cancer. Submitted, 1990.

  45. Kurnick JT, Kradin RL, Blumberg R, Schneeberger EE, Boyle LA. Functional characterization of T lymphocytes propagated from human lung carcinomas. Clin Immunol Immunopathol 1986; 38: 367–80.

    Google Scholar 

  46. Itoh K, Platsoucas CD, Balch CM. Autologous tumorspecific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells and involvement of the T cell receptor. J Exp Med 1988; 168: 1419–41.

    Google Scholar 

  47. Alexander J, Connelly R, Edinger M, Tubbs RR, Boyett J, Pontes E, Bukowski R, Finke JH. Tumor-infiltrating lymphocytes (TIL) from renal cell carcinoma (RCC) and their state of activation: Phenotype and functional analysis. The First International Symphosium on Immunobiology of Renal Cell Carcinoma, The Clevaland Clinic Foundation and Cancer Center, Nov 6–7: 1989, 70.

  48. Belldegrun A, Linehan MW, Robertson CN, Rosenberg SA. Isolation and characterization of lymphocytes infiltrating human renal cell cancer: Possible application for therapeutic adoptive immunotherapy. Surg Forum 1983; 37: 671–73.

    Google Scholar 

  49. Sanders ME, Makgoba MW, Shaw S. Human naive and memory T cells: Reinterpretation of helper-inducer and suppressor-inducer subsets. Immunology Today 1988; 9: 195–9.

    Google Scholar 

  50. Sanders ME, Makgoba MW, Sharrow SO, Stephang D, Springer TA, Young HA, Shaw S. Human memory T lymphocytes express increased levels of three cell adhesion molecules (LFA-3, CD2, and LFA-1) and three other molecules (UCHL1, CDw29 and PgP-1) and have enhanced IFN gamma production. J Immunol 1988; 140: 1401–7.

    Google Scholar 

  51. Finke JH. Tumor infiltrating lymphocytes in RCC; evidence for T cell immune response. The First International Symposium on Immunobiology of Renal Cell Carcinoma, The Cleveland Clinic Foundation and Cancer Center, Nov. 6–7, 1989: 56-9.

  52. Moy PM, Holmes EC, Golub SH. Depression of natural killer cytotoxic activity in lymphocytes infiltrating human pulmonary tumors. Cancer Res 1985; 45: 57–60.

    Google Scholar 

  53. Whiteside TL, Heo DS, Sacchi M, Snyderman C. Antitumor functions of tumor-infiltrating lymphocytes (TIL) separated from human head and neck tumors and grown in recombinant interleukin 2. In: Cortesina G, Krengli M, Pisiani P, Gambaro G, eds:L'Immunotherapia del Tumori della Testa e Collo, Novara, Italy, 1988: 45–55.

  54. Miescher S, Stoeck M, Quiao L, Barras C, Barrelet L, Von Fliedner V. Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res 1988; 48: 6992–8.

    Google Scholar 

  55. Miescher S, Whiteside TL, Moretta L, Von Fliedner V. Clonal and frequency analysis of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 1987; 138: 4004–11.

    Google Scholar 

  56. Miescher S, Whiteside TL, Carrel S, Von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol 1986; 136: 1899–907.

    Google Scholar 

  57. Lettessier E, Sacchi M, Johnson JT, Herberman RB, Whiteside TL. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Cellular Immonol 1990; 130: 446–58.

    Google Scholar 

  58. Mukherji B, Wilhelm SA, Guha A, Ergin MT. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell-mediated supression ofin vitro cytotoxic immune response. J Immunol 1986; 136: 1888–92.

    Google Scholar 

  59. Roth JA, Osborne BA, Ames RS. Immunoregulatory factors derived from human tumors. J Immunol 1983; 130: 303–8.

    Google Scholar 

  60. Botha JH, Robinson KM, Ramchurren N, Reddi K, Norman RJ. Human esophageal carcinoma cell lines: Prostaglandin production, biologic properties, and behavior in nude mice. JNCI 1986; 76: 1053–6.

    Google Scholar 

  61. Wrann M, Bodmer S, de Martin R, Siepl C, Hofer-Warkinek R, Frei K, Hofer G, Fontana A. T-cell suppressor factor from human glioblastoma cells is a 12.5 Kd protein closely related to transforming growth factorβ. EMBO J 1987; 6: 1633–6.

    Google Scholar 

  62. Cianciolo GJ, Copeland TD, Oroszlan S, Snyderman R. Inhibition of lymphocyte proliferation by synthetic peptide homologous to retroviral envelope protein. Science 1985; 230: 453–5.

    Google Scholar 

  63. Ebert EC, Roberts AI, O'Connel SM, Robertson FM, Nagase H. Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol 1987; 138: 2161–8.

    Google Scholar 

  64. Robb RJ. The suppressive effect of gangliosides upon IL2-dependent proliferation as a function of inhibition of IL2 receptor association. J Immunol 1986; 136: 971–6.

    Google Scholar 

  65. Itoh K, Tilden AB, Balch CM. Interleukin 2 activation of cytotoxic T lymphocytes infiltrating into human metastatic melanomas. Cancer Res 1986; 46: 3011–7.

    Google Scholar 

  66. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987; 102: 127–41.

    Google Scholar 

  67. Heo DS, Whiteside TL, Johnson JT, Chen K, Barnes EL, Herberman RB. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res 1987; 47: 6353–62.

    Google Scholar 

  68. Yoo YK, Heo DS, Hata K, Van Thiel DH, Whiteside TL. Tumor infiltrating lymphocytes from human colon carcinomas. Functional and phenotypic characteristics after long-term culture in recombinant interleukin 2. Gastroenterology 1990; 98: 259–68.

    Google Scholar 

  69. Beldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor infiltrating lymphocytes in human renal cell cancer. Isolation, characterization and antitumor activity. Cancer Res 1988; 48: 206–14.

    Google Scholar 

  70. Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 1987; 138: 989–95.

    Google Scholar 

  71. Shimizu Y, Iwatsuki S, Herberman RB, Whiteside TL. Effects of cytokines onin vitro outgrowth of tumor-infiltrating lymphocytes obtained from human primary and metastatic liver tumors. Cancer Immunol Immunother 1991; 32: 280–8.

    Google Scholar 

  72. Whiteside TL, Heo DS, Takagi S, Herberman RB. Characterization of novel antitumor effector cells in longterm cultures of human tumor-infiltrating lymphocytes. Transpl Proc 1988; 20: 347–8.

    Google Scholar 

  73. Fossati G, Radizzani M, Quaia M, Galligioni E, Parmiani G. Lymphocytes from cancer patients contain CD3+CD4+ cells which require the presence of both autologous tumor cells and interleukin 2 to proliferatein vitro. Proc AACR 1989; 30: 353.

    Google Scholar 

  74. Shu S, Rosenberg SA. Adoptive immunotherapy of newly induced sarcoma: Immunologic characteristics of effector cells. J Immunol 1985; 135: 2895–903.

    Google Scholar 

  75. Chou T, Chang AE, Shu S. Generation of therapeutic T lymphocytes from tumor-bearing mice byin vitro sensitization. Culture requirements and characterization of immunologic specificity. J Immunol 1988; 140: 2453–61.

    Google Scholar 

  76. Knuth A, Danowski B, Oettgen HF, Old LJ. T cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T cell cultures. PNAS USA 1984; 81: 3511–5.

    Google Scholar 

  77. Slingluff CO, Darrow T, Verbarer TC, Quinn-Allen MA, Siegler HP. Human cytotoxic T cells specific for autologous melanoma cells. Successful generation from lymph node cells in seven consecutive cases. JNCI 1988; 18: 1016–26.

    Google Scholar 

  78. Mukherji B, Ergin MT, Guha A, Chakraborty NG, Sivanandham M, Nashed AL, Sporn JR: Clonal analysis and regulatory T cell responses against human melanoma. J Exp Med 1989; 169: 1961–76.

    Google Scholar 

  79. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, et al. Use of tumor-infiltrating lymphocytes and interleukin 2 in the immunotherapy of patients with metastatic melanoma. New England J Med 1988; 319: 1675–1680.

    Google Scholar 

  80. Barnd DL, Lamm S, Metzgar RS, Finn OJ. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. PNAS USA 1989; 86: 7159–63.

    Google Scholar 

  81. Gately MK, Wilson DE, Wong HL. Synergy between recombinant interleukin-2 (rIL2) and IL2 depleted lymphokine-containing supernatants in facilitating allogeneic human cytolytic T lymphocytein vitro. J. Immunol 1986; 136: 1274–82.

    Google Scholar 

  82. Giovarelli M, Santoni A, Jemma C, Musso T, Guiffrida AM, Cavallo G, Landolfo S, Forni G. Obligatory role of interferon γ in induction of lymphokine-activated and T-interferon γ in induction of lymphokine-activated and T-lymphocyte killer activity, but not in boosting of natural cytotoxicity. J. Immunol 1988; 141: 2831–6.

    Google Scholar 

  83. Wang YL, Si L, Kanbour A, Herberman RB, Whiteside TL. Lymphocytes infiltrating human ovarian tumors: Synergy between tumor necrosis factorα and interleukin 2 in the generation of CD8+ effectors from tumorinfiltrating lymphocytes. Cancer Res 1989; 49: 5979–85.

    Google Scholar 

  84. Ranges GE, Figari IS, Espevik T, Palladino MA, Jr. Inhibition of cytotoxic T cell development by transforming growth factor-β and reversal by recombinant tumor necrosis factorα. J Exp Med 1987; 166: 991–8.

    Google Scholar 

  85. de Vries JE, Spits H. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I.In vitro generation, isolation, and analysis of phenotype and specificity. J Immunol 1984; 132: 510–9.

    Google Scholar 

  86. Guerry D, Alexander MA, Herlyn MF, Zehngebot LM, Mitchell KF, Zmijewski CM, Lusk EJ. HLA-DR histocompatibility leucocyte antigens permit human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest 1984; 73: 267–71.

    Google Scholar 

  87. Barnd D, Kerr L, Metzgar RS, Finn OJ. Tumor specific cytotoxic T cell lines generated from tumor-draining lymph node infiltrate. Transpl Proc 1988; 20: 339–41.

    Google Scholar 

  88. Ferrini S, Biassoni R, Moretta A, Bruzzone M, Nicolin A, Moretta L. Clonal analysis of T lymphocytes isolated from ovarian carcinoma ascitic fluid. Phenotypic and functional characterizations of T-cell clones capable of lysing autologous carcinoma cells. Int J Cancer 1985; 36: 337–43.

    Google Scholar 

  89. Sato T, Sato N, Takahashi S, Koshiba H, Kikuchi K. Specific cytotoxicity of a long-term cultured T cell clone on human autologous mammary cancer cells. Cancer Res 1986; 46: 4384–9.

    Google Scholar 

  90. Miyatake S, Handa H, Yamashita J, Yamasaki T, Veda M, Namba Y, Hanaoka M. Induction of human gliomaspecific cytotoxic T-lymphocyte lines by autologous tumor stimulation and interleukin 2. J Neuro-Oncol 1986; 4: 55–64.

    Google Scholar 

  91. Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986; 223: 1318–21.

    Google Scholar 

  92. Topalian SL, Solomon D, Avis FP, Chang AE, Freersken DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin 2: A pilot study. J Clin Oncol 1988; 6: 839–53.

    Google Scholar 

  93. Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ, Strauss HW Tumor-infiltrating lymphocytes and interleukin-2 treatment of advanced cancer. Lancet 1989; March 18: 557–80.

    Google Scholar 

  94. Kawakami Y, Rosenberg SA, Lotze MT. Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 1988; 168: 2183–91.

    Google Scholar 

  95. Stotter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT. Cytokines alter target cell susceptibility to lysis. II. Evaluation of tumorinfiltrating lymphocytes. J Immunol 1989; 142: 1767–73.

    Google Scholar 

  96. Tatake RJ, Guha A, Mukherji B. Activation of autoreactive cytolytic T lymphocyte clone against human melanoma by anti-T3 monoclonal antibody and autologous accessory cells. Cell Immunol 1987; 108: 42–52.

    Google Scholar 

  97. Hersey P, MacDonald M, Werkman H. Western blot analysis of antigens on melanoma cells recognized by cytotoxic T cells. JNCI 1988; 80: 826–35.

    Google Scholar 

  98. Knuth A, Wölfel T, Klehmann E, Boon T, Meyer zum Büschenfelde K-M. Cytotoxic T cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection. PNAS USA 1989; 86: 2804–8.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, University of Pittsburgh School of Medicine and Pittsburgh Cancer Institute, 15213, Pittsburgh, PA, USA

    Theresa L. Whiteside

Authors
  1. Theresa L. Whiteside
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Whiteside, T.L. Tumor-infiltrating lymphocytes as antitumor effector cells. Biotherapy 5, 47–61 (1992). https://doi.org/10.1007/BF02194785

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02194785

Keywords

Search

Navigation